Satralizumab is safe and effective for patients with myelin oligodendrocyte glycoprotein antibody-associated disease, the new ...

Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic ...

Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...

Henlius (02696.HK) announced that a Phase 2/3 clinical trial of its self-developed pimurutamab HLX07 (recombinant anti-EGFR ...

Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...

Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. Breast cancer frequently overexpresses the product of the ...

Additional Prognostic Value of Bone Marrow Histology in Patients Subclassified According to the International Prognostic Scoring System for Myelodysplastic Syndromes Purpose: To evaluate the ...

Monoclonal antibodies (mAbs) are highly specific, laboratory-produced antibodies designed to target a single specific epitope or binding site on an antigen. Unlike polyclonal antibodies, which are a ...